Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2017 December;108(6) > Minerva Medica 2017 December;108(6):568-74

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW   

Minerva Medica 2017 December;108(6):568-74

DOI: 10.23736/S0026-4806.17.05094-7

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

SNHG and UCA1 as prognostic molecular biomarkers in hepatocellular carcinoma: recent research and meta-analysis

Jiaqi LI, Jing GAO, Ao KAN, Tian HAO, Ling HUANG

The Second Affiliated Hospital of Nanchang University, Nanchang, China


PDF


INTRODUCTION: The latest studies have shown that the long non-coding RNAs seemed to be qualified markers of cancer. So we sought to assess the prognostic value of SNHG and UCA1 as predictive markers of patients with hepatocellular carcinoma (HCC).
EVIDENCE ACQUISITION: Relevant literatures were collected in PubMed and Embase. Measuring the expression of specific SNHG or UCA1 in tissue or serum and studying their association with survival outcome. Survival outcome was further explored considering the hazard ratio (HR) with confidence interval (CI).
EVIDENCE SYNTHESIS: We found that patients with higher expression of pooled SNHG/UCA1 had significant poor overall survival (HR 1.74; 95% CI: 1.05-2.89), and also significant for only SNHG (HR 2.05; 95% CI: 1.06-3.96). Over-expression of UCA1 may predict meaningless overall survival (HR 1.31; 95% CI: 0.57-3.03; P=0.53).
CONCLUSIONS: Our meta-analysis demonstrated that SNHG and UCA1 may serve as prognostic biomarkers for HCC prognosis.


KEY WORDS: Carcinoma, hepatocellular - Prognosis - RNA, long noncoding - Biomarkers

top of page